Clinical Trials Browser

Phase 1 × INDUSTRY × CT103A chimeric antigen receptor × Clear all

NCT05698303 2023-01-26

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Unknown

Multiple Myeloma

NCT05181501 2022-01-06

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Phase 1 Not yet recruiting

Multiple Myeloma